Last reviewed · How we verify
NCT06929910: GS_ZKM
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
trial in Metastatic Cancers in 200 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Gene Solutions |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 9 April 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across Vietnam |
Conditions studied
- Metastatic Cancers — all drugs for Metastatic Cancers →
Sponsor
Gene Solutions
Who can join
Eligibility, any sex, with Metastatic Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who have undergone K4Care testing
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06929910
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Cancers
Currently open trials in the same condition.
- NCT07236021 — e-Motion : Promoting Emotion Regulation in Chronic Cancer · NA · recruiting
- NCT06678659 — A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer · Phase 1, PHASE2 · recruiting
- NCT06085716 — Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers · Phase 2, PHASE3 · recruiting
- NCT02304809 — Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations · Phase 2 · active not recruiting
Other Gene Solutions trials
Trials by the same sponsor.
- NCT07126626 — Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer · not yet recruiting
- NCT06385366 — Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test · enrolling by invitation
- NCT06227728 — Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer. · recruiting
- NCT06167460 — Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. · recruiting
- NCT06087120 — Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06929910 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gene Solutions
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06929910.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing